Late-stage trial shows MS drug effectiveness, Novartis says

12/14/2008 | Wall Street Journal, The

Novartis AG reported preliminary data from a late-stage trial showing that 0.5 mg and 1.25 mg doses of FTY720, a drug candidate for multiple sclerosis, were more effective in reducing relapse than Avonex, an injectable drug from Biogen Idec. Novartis said it may seek FDA approval for FTY720 at the end of next year.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST
Matheson Tri-Gas, Inc.
Newark, CA
Catheter Engineer
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
MANAGER MEDICAL GAS COMPLIANCE AND SAFETY
Matheson Tri-Gas, Inc.
Houston, TX
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations